Spots Global Cancer Trial Database for Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Official Title: A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Study ID: NCT03055286
Conditions
Interventions
Study Description
Brief Summary: This is a multicenter (S. Korea/US), Phase Ib, open-label, dose-finding study to assess safety, PK, PD, and preliminary efficacy of CWP232291 administered in combination with ara-C in subjects with relapsed or refractory AML. The primary objectives in phase 2a is to assess the efficacy of CWP232291 administered in combination with cytarabine (response rate complete remission \[RR-CR\]/complete remission with incomplete blood count recovery \[CRi\]/partial remission \[PR\]).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Washington, Seattle, Washington, United States
Samsung medical center, Seoul, Gangnam-gu, Korea, Republic of
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
Asan Medical Center, Seoul, Songpa-Gu, Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
